Agonists that deplete intracellular Ca 2+ stores also activate Ca 2+ entry, although the mechanism by which store release and Ca 2+ influx are linked is unclear. A potential mechanism involves 'storeoperated channels' that respond to depletion of the intracellular Ca 2+ pool. Although SOCE (store-operated Ca 2+ entry) has been considered to be the principal route for Ca 2+ entry during hormonal stimulation of non-electrically excitable cells, recent evidence has suggested that alternative pathways activated by metabolites such as arachidonic acid are responsible for physiological Ca 2+ influx. It is not clear whether such messenger-activated pathways exist in all cells, whether they are truly distinct from SOCE and which metabolites are involved. In the present study, we demonstrate that HeLa cells express two pharmacologically and mechanistically distinct Ca 2+ entry pathways. One is the ubiquitous SOCE route and the other is an arachidonate-sensitive non-SOCE. We show that both these Ca 2+ entry pathways can provide longlasting Ca 2+ elevations, but that the channels are not the same, based on their differential sensitivity to 2-aminoethoxydiphenyl borate, LOE-908 {(R,S)- (3,4-dihydro-6,7-dimethoxy- -(2,3,4-trimethoxyphenyl)ethyl]acetamid mesylate} and gadolinium. In addition, non-SOCE and not SOCE was permeable to strontium. Furthermore, unlike SOCE, the non-SOCE pathway did not require store depletion and was not sensitive to displacement of the endoplasmic reticulum from the plasma membrane using jasplakinolide or ionomycin pretreatment. These pathways did not conduct Ca 2+ simultaneously due to the dominant effect of arachidonate, which rapidly curtails SOCE and promotes Ca 2+ influx via non-SOCE. Although non-SOCE could be activated by exogenous application of arachidonate, the most robust method for stimulation of this pathway was application of the widely used calmodulin antagonist calmidazolium, due to its ability to activate phospholipase A 2 .
Agonists that deplete intracellular Ca 2+ stores also activate Ca 2+ entry, although the mechanism by which store release and Ca 2+ influx are linked is unclear. A potential mechanism involves 'storeoperated channels' that respond to depletion of the intracellular Ca 2+ pool. Although SOCE (store-operated Ca 2+ entry) has been considered to be the principal route for Ca 2+ entry during hormonal stimulation of non-electrically excitable cells, recent evidence has suggested that alternative pathways activated by metabolites such as arachidonic acid are responsible for physiological Ca 2+ influx. It is not clear whether such messenger-activated pathways exist in all cells, whether they are truly distinct from SOCE and which metabolites are involved. In the present study, we demonstrate that HeLa cells express two pharmacologically and mechanistically distinct Ca 2+ entry pathways. One is the ubiquitous SOCE route and the other is an arachidonate-sensitive non-SOCE. We show that both these Ca 2+ entry pathways can provide longlasting Ca 2+ elevations, but that the channels are not the same, based on their differential sensitivity to 2-aminoethoxydiphenyl borate, LOE-908 {(R,S)- (3,4-dihydro-6,7 -dimethoxy-isochinolin-1-yl)-2-phenyl-N,N-di[2-(2,3,4-trimethoxyphenyl)ethyl]acetamid mesylate} and gadolinium. In addition, non-SOCE and not SOCE was permeable to strontium. Furthermore, unlike SOCE, the non-SOCE pathway did not require store depletion and was not sensitive to displacement of the endoplasmic reticulum from the plasma membrane using jasplakinolide or ionomycin pretreatment. These pathways did not conduct Ca 2+ simultaneously due to the dominant effect of arachidonate, which rapidly curtails SOCE and promotes Ca 2+ influx via non-SOCE. Although non-SOCE could be activated by exogenous application of arachidonate, the most robust method for stimulation of this pathway was application of the widely used calmodulin antagonist calmidazolium, due to its ability to activate phospholipase A 2 . 2+ ) is a universal and versatile intracellular messenger that regulates a diverse range of cellular processes [1] . Cells have access to two sources of calcium, finite stores located in intracellular organelles and a more substantial pool of extracellular Ca 2+ . In many cells types, release of Ca 2+ from intracellular stores leads to the activation of a Ca 2+ influx pathway denoted as SOCE (store-operated Ca 2+ entry) [2] . This mechanism for promoting Ca 2+ entry is responsible for replenishing depleted intracellular stores and prolonging cellular Ca 2+ signals [3] . The molecular identity of the channels responsible for SOCE and their precise mechanism of activation are unclear. The probable candidates are members of the TRPC (canonical transient receptor potential) family [3, 4] . Several studies support this hypothesis and have shown that the expression or ablation of various TRPC isoforms can modulate SOCE responses (see e.g. [5] [6] [7] ).
INTRODUCTION

Calcium (Ca
A prominent model for the stimulation of TRPs during SOCE activation proposes a direct interaction between these plasma membrane channels and Ca 2+ release channels on the intracellular stores. The latter would serve to sense a decrease in luminal Ca 2+ concentration, and via a conformational change transmit this information to promote SOCE channel opening [2, 3, 8, 9] . A direct Abbreviations used: AA, arachidonic acid; ACA, N-(p-amylcinnamoyl) anthranillic acid; 2-APB, 2-aminoethoxydiphenyl borate; CaM, calmodulin; DAG, diacylglycerol; GFP, green fluorescent protein; EGFP, enhanced GFP; EM, extracellular medium; ER, endoplasmic reticulum; Ins(1,4,5)P 3 R, inositol 1,4,5-trisphosphate receptor; LOE-908, (R,S)-(3,4-dihydro-6,7-dimethoxy-isochinolin-1-yl)-2-phenyl-N,N-di[2-(2,3,4-trimethoxyphenyl)ethyl]acetamid mesylate; PKC, protein kinase C; PLA 2 , phospholipase A 2 ; PLC, phospholipase C; RyR, ryanodine receptor; SOCE, store-operated Ca 2+ entry; TFP, trifluoperazine; TRPC, canonical transient receptor potential; W-7, N-(6-aminohexyl)-5-chloro-1-naphthalenesulphonamide. 1 These authors have contributed equally to this work. 2 Present address: Department of Oral Biology, BK21 Project for Medical Sciences, Yonsei University College of Dentistry, Seoul, South Korea. 3 To whom correspondence should be addressed (e-mail martin.bootman@bbsrc.ac.uk).
interaction between TRPs and two families of intracellular Ca 2+ release channel, Ins(1,4,5)P 3 Rs (inositol 1,4,5-trisphosphate receptors) and RyRs (ryanodine receptors) has been demonstrated [10, 11] (see [3, 12] for reviews). When the Ca 2+ concentration on the luminal domain of Ins(1,4,5)P 3 Rs or RyRs is sufficiently low, this interaction can lead to TRP channel activation. Interventions that prevent the coupling of intracellular channels with TRPs, using either peptides that prevent the interaction (see e.g. [13] ) or formation of a subplasmalemmal actin barrier [14, 15] , inhibit SOCE activation.
SOCE can be readily demonstrated in almost all non-electrically excitable cells and in some excitable cells after hormonal/ neurotransmitter stimulation or depletion of intracellular Ca 2+ stores using SERCA (sarcoplasmic/endoplasmic-reticulum Ca 2+ -ATPase) inhibitors, such as thapsigargin [2, 3, 9, 12] . The broad expression of the SOCE pathway has led to it being considered a prominent mechanism for Ca 2+ entry into cells after Ca 2+ pool discharge. However, it is becoming increasingly apparent that stimulation of cells with hormones that invoke the production of Ca 2+ -releasing messengers not only activates SOCE, but can also promote additional Ca 2+ entry pathways [16, 17] . When Ins(1,4,5)P 3 is produced after phosphoinositide hydrolysis, there is a concomitant production of DAG (diacylglycerol).
Unlike water-soluble Ins(1,4,5)P 3 , DAG stays in the plane of the plasma membrane where it can activate PKC (protein kinase C) or is metabolized further. Both PKC and DAG (or membranepermeant analogues) have been demonstrated to cause Ca 2+ influx distinct from SOCE in some cell types [18, 19] . Furthermore, other messengers resulting from DAG metabolism, including AA (arachidonic acid) and leukotrienes, activate non-SOCE Ca 2+ influx [20] [21] [22] . The molecular target of these messengers is not established, although TRPC isoforms have again been implicated. Although there are an increasing number of reports demonstrating significant Ca 2+ influx via non-SOCE, at present, it is not clear whether all cells employ a non-SOCE mechanism, and if so, in response to which messenger. Probably, the best-characterized non-SOCE activator is AA. Studies from both the Shuttleworth [21] and Taylor [20] [23, 24] . For Ins(1,4,5)P 3 Rs this is a largely negative effect, whereas for RyRs CaM can mediate both inhibition and activation (see [25, 26] for reviews). CaM has also been demonstrated to modulate negatively Ca 2+ influx through SOCE and TRP channels [27] [28] [29] [30] .
A common approach in investigating the action of CaM has been to use membrane-permeant pharmacological antagonists such as calmidazolium, W-7 [N-(6-aminohexyl)-5-chloro-1-naphthalenesulphonamide] and TFP (trifluoperazine). However, these agents have been shown to cause robust Ca 2+ signals albeit through unknown mechanisms. Calmidazolium, for example, has been shown to cause Ca 2+ release and Ca 2+ entry in Dictyostelium [31] , platelets [32] , thyroid FRTL-5 cells [33] , Madin-Darby canine kidney cells [34] and HL-60 cells [35] . These responses could be consistent with CaM causing a tonic inhibition of Ca 2+ channels, which is relieved during activation or application of CaM antagonists.
We investigated the mechanism by which agents such as calmidazolium triggered Ca 2+ increases using HeLa cells. Calmidazolium was capable of evoking Ca 2+ signals that fully mimicked those stimulated by Ins(1,4,5)P 3 -generating agonists in all respects except for the pathway through which Ca 2+ influx occurred, i.e. via non-SOCE and not via SOCE.
MATERIALS AND METHODS
HeLa cell culture
HeLa cell culture was performed as described previously [36] . All experimental procedures were performed at room temperature (20) (21) (22) • C). Before imaging, the culture medium was replaced with an EM (extracellular medium) containing (mM): NaCl, 121; KCl, 5.4; MgCl 2 , 0.8; CaCl 2 , 1.8; NaHCO 3 , 6; D-glucose, 5.5; Hepes, 25 (pH 7.3). Histamine, calmidazolium, U73122 and thapsigargin were obtained from Sigma. Fura 2 was obtained from Molecular Probes (Eugene, OR, U.S.A.). Statistics were performed using Student's t test (GraphPad Prism, San Diego, CA, U.S.A.).
Video imaging
Measurement of cytosolic Ca 2+ in HeLa cells was performed by monitoring fura 2 fluorescence of cells adhered to glass coverslips using either a Spex or a PerkinElmer imaging system. Fura 2 was loaded into the cells by incubation with 2 µM fura 2 acetoxymethyl ester (30 min incubation followed by a 30 min period for de-esterification). For the Spex system, cells on coverslips were mounted on a Nikon Diaphot inverted epi-fluorescence microscope. Fluorescent images were obtained by alternate 40 ms excitations at 340 and 380 nm using twin xenon arc lamps each coupled with a spex monochrometer (Spex Industries, Edison, NJ, U.S.A.), with the wavelengths being switched by a rotating chopper mirror (Glen Creston Instruments, Stanmore, U.K.). Emission signals at 510 nm were collected using an intensified charge-coupled device video camera (Photonics Science, Robertson, U.K.) and filtered with a 200 ms time constant (Spex system) before off-line storage for analysis using an Imagine image processing system (Synoptics, Cambridge, U.K.).
With the PerkinElmer system, a single glass coverslip with adherent cells was mounted on the stage of a Nikon Diaphot 300 inverted epi-fluorescence microscope coupled with a xenon arc lamp (Nikon, Tokyo, Japan) light source. Fluorescence images were obtained with alternate excitations at 340 and 380 nm, selected for using either a Sutter filter wheel (340HT15 and 380HT15; Sutter Industries, Novarta, CA, U.S.A.) or a Spectramaster II monochrometer. Emitted light was filtered at 510 nm and collected by a cooled Astrocam digital camera. The acquired images were stored and subsequently processed off-line with Ultraview software (PerkinElmer LifeSciences, Great Shelford, Cambridge, U.K. The cDNA encoding the type 1 Ins(1,4,5)P 3 5 -phosphatase was amplified by PCR from a cDNA clone kindly provided by Professor C. Erneux (Université Libre de Bruxelles, Brussels, Belgium) and subcloned into pdc515-EGFP-C1 (where EGFP stands for enhanced green fluorescent protein). All constructs were transiently transfected using GeneJuice TM (Novagen, Nottingham, U.K.), according to the manufacturer's instructions. Briefly, 24 h before transfection, cells were seeded on to 22 mm glass coverslips at 50-80 % confluency. Cells were incubated for 24 h post-transfection at 37
• C, in 5 % CO 2 atmosphere with saturated humidity to allow expression of the construct. GFPtagged actin was transfected into cells using the same procedure.
Jasplakinolide treatment
To stimulate cortical actin polymerization, cells were incubated for 30 min at 22
• C, with 10 µM jasplakinolide in nominally Ca 2+ free solution. To confirm the effect of jasplakinolide on actin rearrangement, images of cells expressing GFP-tagged actin were acquired using a Bio-Rad MRC1024 confocal laser-scanning microscope (× 60 objective; 1.4 NA). GFP was excited using a 488 nm laser line and emission was collected through a 505 nm long-pass filter. Optical sections were taken every 0.4 µm. Image analysis and processing were performed with the public domain software ImageJ (NIH, http://rsb.info.nih.gov.ij).
Preparation and storage of AA
Porcine liver AA (Na + salt; Calbiochem) was dissolved in MilliQ water as a concentrated stock solution before being dispensed in aliquots; they were then frozen and stored at − 20
• C in a lightresistant container. Before use, an aliquot of AA was diluted to the required concentration by addition of EM containing 0.1 % DMSO (to aid membrane permeability). All samples of AA were kept in the dark and on ice to suppress oxidation.
Use of Ba
2+ as a Ca 2+ surrogate
For some experiments, Ba 2+ was used to monitor cation entry in place of Ca 2+ . Ba 2+ had been used in previous studies as a Ca 2+ surrogate to provide a measure of unidirectional cation flux, since it was poorly sequestered by intracellular Ca 2+ pumps or extruded from cells. Increases in cytosolic Ba 2+ were monitored using fura 2 as described above, using the same excitation and emission settings as for Ca 2+ . The results are presented as uncalibrated ratio (emission at 340 nm/excitation at 380 nm) units.
For the experiments shown in Figure 8 , Ba 2+ was employed simply because we could not use calcium with ionomycintreated cells, since it would be impossible to identify Ca 2+ that entered cells through the ionophore or via SOCE/non-SOCE. In our experiments, Ba 2+ did not permeate into cells via ionomycin.
RESULTS
CaM antagonist calmidazolium evokes calcium release and activates a non-SOCE
CaM has been proposed to suppress the activation of both Ins(1,4,5)P 3 Rs and SOCE channels. A common method of antagonizing the action of CaM is to use membrane-permeant pharmacological antagonists, such as calmidazolium, W-7 and TFP. Consistent with the idea that CaM antagonists relieve CaMdependent inhibition of Ca 2+ channels, these compounds have all been demonstrated to cause Ca 2+ signals within intact cells. However, it has not been established whether their cellular target is CaM or other processes involved in Ca 2+ signal transduction. We therefore determined whether there was a direct effect of CaM antagonists on the activity of Ins(1,4,5)P 3 Rs and SOCE channels. We initially concentrated on the action of the imidazole compound calmidazolium, since this has been widely used to abrogate effects of CaM and has also been shown to activate Ca 2+ mobilization and Ca 2+ entry. When applied in Ca 2+ -free medium, calmidazolium evoked a rapid transient increase in cytosolic Ca 2+ ( Figure 1A ; average peak response 462 + − 44 nM; n = 126 cells), which was followed by robust calcium entry when extracellular calcium was replaced (average response 935 + − 71 nM; n = 126 cells). Effects of calmidazolium were reversible, since pulsatile application caused repetitive Ca 2+ responses ( Figure 1B ). Calmidazolium evoked concentration-dependent Ca 2+ increases ( Figure 1C) , with all cells responding to doses of calmidazolium > 2 µM (n > 600 cells from 20 independent experiments). At concentrations 1 µM calmidazolium, global Ca 2+ responses were not observed. Instead, subcellular Ca 2+ transients that we, and others, have described as 'Ca 2+ puffs' [37] were evoked (results not shown). The Ca 2+ pool mobilized by calmidazolium overlapped largely with the Ins(1,4,5)P 3 -sensitive Ca 2+ store. Application of a maximal histamine concentration (100 µM) in Ca 2+ -free medium to deplete the Ins(1,4,5)P 3 -sensitive Ca 2+ pools decreased the response to a subsequent addition of calmidazolium (10 µM) usually to a single low-amplitude Ca 2+ transient ( Figure 1D ). In the reciprocal experiment, application of a maximal calmidazolium concentration (10 µM) in Ca 2+ -free medium substantially reduced the magnitude of response observed with an ensuing histamine challenge ( Figure 1E ). When applied to naive cells, 100 µM histamine evoked an average peak Ca 2+ increase in 763 + − 12 nM (n = 49 cells). After calmidazolium treatment, histamine responses were reduced to 283 + − 16 nM (n = 37 cells). With cells in Ca 2+ -free medium, but not Ca 2+ -containing medium, calmidazolium frequently triggered Ca 2+ oscillations that were similar in rise time and duration to those observed during hormonal stimulation (cf. Figures 1D and 1E) .
Calmidazolium-activated Ca 2+ signals described above were comparable in almost all respects with typical responses triggered by hormonal stimulation of HeLa cells [38] . Similar to hormonal agonists, it appeared that calmidazolium was capable of releasing the Ins(1,4,5)P 3 -sensitive Ca 2+ store and triggering Ca 2+ entry. To determine the mechanism by which calmidazolium could activate Ca 2+ release, we examined the effects of well-known inhibitors of PLC (phospholipase C) and Ins(1,4,5)P 3 Rs. Application of the PLC inhibitor U73122 at a concentration that blocks agonistevoked Ca 2+ signalling in HeLa cells [39] completely inhibited Ca 2+ mobilization by calmidazolium (Figure 2A) . Whereas all cells responded to 10 µM calmidazolium under control conditions (see above), no cells displayed Ca 2+ mobilization in response to 10 µM calmidazolium in the presence of U73122. The inactive analogue U73343 did not prevent Ca 2+ release activated by 10 µM calmidazolium (n = 60 cells; results not shown). 2-APB (2-aminoethoxydiphenyl borate), which we have demonstrated previously to inhibit Ins(1,4,5)P 3 -induced Ca 2+ release in HeLa cells [40] , also prevented Ca 2+ mobilization by calmidazolium ( Figure 2B) . Caffeine, which acts as a combined blocker of PLC and Ins(1,4,5)P 3 Rs, also prevented calmidazolium-evoked Ca 2+ release ( Figure 2C ). Heterologous expression of the 5 -phosphatase enzyme, which degrades Ins(1,4,5)P 3 to the non-Ca 2+ releasing metabolite Ins(1,4)P 2 , prevented Ca 2+ mobilization in response to either a maximal histamine concentration (100 µM) or a maximal calmidazolium dose (10 µM; Figure 2D ). Since calmidazolium has been shown previously to activate PLC activity [34] , the simplest interpretation of the results presented above is that calmidazolium mobilizes Ca 2+ stores by activation of PLC. Therefore, with respect to Ca 2+ release from Ins(1,4,5)P 3 Rs, calmidazolium mimics an Ins(1,4,5)P 3 -generating agonist.
Although the mobilization of Ins(1,4,5)P 3 -sensitive Ca 2+ stores by calmidazolium can be ascribed to activation of PLC, the entry of Ca 2+ in calmidazolium-treated cells appears to occur via a distinct mechanism. None of the agents that blocked calmidazoliuminduced Ca 2+ mobilization (Figures 2A-2C) inhibited Ca 2+ entry when Ca 2+ was reapplied to cells. In addition, expression of the 5 -phosphatase enzyme to levels that completely abrogated histamine-evoked Ca 2+ signals and prevented calmidazolium causing Ca 2+ release ( Figure 2D ), did not inhibit calmidazolium-induced Ca 2+ entry ( Figure 2E ). Furthermore, similar to previous results [41] , we have demonstrated that 2-APB completely inhibited SOCE in HeLa cells [40] , yet it did not prevent calmidazolium-induced Ca 2+ influx ( Figure 2B ). These results indicate that calmidazolium activated a Ca 2+ entry pathway that was distinct from that triggered by store depletion.
Calmidazolium-activated non-SOCE is pharmacologically distinct from SOCE
Calmidazolium induced an additional increase in the plateau Ca 2+ level after full SOCE activation by application of a maximal concentration of thapsigargin (2 µM; Figure 3A) , which was completely blocked by the cation channel inhibitor LOE-908 [2-(2,3,4-trimethoxyphenyl) ethyl]acetamid mesylate} (Figure 3B) . In contrast, LOE-908 gave only a modest inhibition of Ca 2+ entry stimulated by thapsigargin ( Figures 3C and 3D ). Gadolinium (Gd 3+ ) has been used previously as a high-affinity irreversible inhibitor of SOCE (see e.g. [42] ). We similarly observed that 1 µM Gd 3+ completely blocked Ca 2+ influx evoked by application of thapsigargin ( Figure 4A ). However, Gd 3+ had only a partial effect on calmidazolium-induced Ca 2+ entry when applied at concentrations 10 µM ( Figure 4B ). The weak effect of Gd 3+ on calmidazolium-evoked bivalent cation entry was also observed by substituting extracellular Ca 2+ with manganese (Mn 2+ ) and by following the quenching of fura 2 fluorescence as Mn 2+ entered the cells. Calmidazolium evoked a significant increase in the rate of Mn 2+ entry ( Figure 4C ), which was unaffected by the presence of Gd 3+ ( Figure 4D ). A further difference in cation sensitivity of the two influx pathways was observed when Ca 2+ in the EM was substituted by strontium (Sr 2+ ). The SOCE pathway in HeLa cells did not appreciably conduct Sr 2+ , whereas Sr 2+ entry was readily detectable after calmidazolium treatment ( Figure 4E) . A summary of the pharmacological distinction between SOCE and the Ca 2+ entry pathway activated by calmidazolium is shown in Figure 4(F) .
During prolonged activation, SOCE-mediated Ca 2+ influx diminishes despite intracellular Ca 2+ stores remaining empty (see e.g. [43, 44] ; Figure 5A ). This has been demonstrated to be due to progressive inhibition of the Ca 2+ entry pathway and acceleration of Ca 2+ sequestration [44] . Approx. 20 min after stimulation with thapsigargin, the cytosolic Ca 2+ concentration had returned to the resting level. Subsequent application of calmidazolium provoked a steep increase in Ca 2+ ( Figure 5A ), which was abolished by LOE-908 (results not shown). By itself, LOE-908 had little effect on the time course of thapsigargin-evoked SOCE (results not shown). Although the amplitude of both SOCE-and calmidazolium-evoked Ca 2+ entries varied between cells, the latter pathway generally produced larger Ca 2+ signals, as illustrated in Figure 5 (B). For the experiment depicted in Figure 5 (B), the mean peak amplitudes for Ca 2+ entry through SOCE-and calmidazolium-sensitive pathway were 117 + − 33 and 275 + − 36 nM respectively (n = 30; P < 0.002).
In a recent study, Bolotina and co-workers [45] utilized calmidazolium to activate SOCE in smooth-muscle cells. They demonstrated that low concentrations of calmidazolium specifically activated SOCE, as judged by complete abolition of Ca 2+ influx with 2-APB. At higher concentrations of calmidazolium, they found that the Ca 2+ entry was insensitive to 2-APB. We observed a similar concentration-dependent action of calmidazolium. 2-APB suppressed responses to low ( 2.5 µM), but not high ( 5 µM), calmidazolium concentrations ( Figure 1C ). Similar to Bolotina and co-workers, we interpret these results as indicating that calmidazolium has distinct effects at low and high concentrations. Low concentrations activate SOCE, whereas higher doses switch the Ca 2+ entry to 2-APB-insensitive non-SOCE.
Bolotina and co-workers [45] suggested that low calmidazolium concentrations activated SOCE in the absence of calcium release. In contrast, using real-time confocal microscopy, we observed that Ca 2+ release was the earliest response of the cells to calmidazolium. As described above, concentrations of 1 µM calmidazolium triggered Ca 2+ puffs, which can lead to Ca 2+ waves [37] . Therefore the most sensitive response of cells to calmidazolium is Ca 2+ release, not Ca 2+ entry.
Calmidazolium activates the same non-SOCE pathway as AA in HeLa cells
Various messengers and metabolites have been shown to activate Ca 2+ influx independently of Ca 2+ store release, including PKC, DAG and AA. We therefore used established pharmacological agents to probe the contribution of these moieties in calmidazolium-activated Ca 2+ entry. Treatment of cells with the PKC activators PMA (1 µM; n = 50 cells) or 1-oleoyl-2-acetyl-sn-glycerol (1 µM; n = 90 cells) neither caused Ca 2+ increase nor prevented Ca 2+ response to calmidazolium when perfused on to cells for up to 30 min. The DAG lipase inhibitor, RHC-80267, has been used in previous Mammalian cells express a diverse array of PLA 2 (phospholipase A 2 ) subtypes [46] . In the present study, three PLA 2 inhibitors, ACA [N-(p-amylcinnamoyl) anthranillic acid], isotetrandrine and AACOCF 3 (arachidonyltrifluoromethyl ketone), were used to investigate the role of PLA 2 Figure 6A ). The ability of ACA to prevent calmidazolium-induced Ca 2+ signals implicates AA or one of its metabolites as the critical messenger(s) underlying the activation of the non-SOCE Ca 2+ influx pathway described above. Consistent with the notion that calmidazolium stimulates PLA 2 and that the resultant AA production activates Ca 2+ signalling, direct application of 10 µM AA to cells in the presence of ACA evoked both Ca 2+ mobilization and Ca 2+ entry ( Figure 6B ). To confirm that AA and calmidazolium were activating the same Ca 2+ influx pathway, we examined the pharmacological profile and cation sensitivity of the Ca 2+ signals evoked by direct AA application. Similar to calmidazolium, Ca 2+ entry stimulated by 10 µM AA was not inhibited by 100 µM 2-APB ( Figure 7A ) or 10 µM U73122 ( Figure 7B ) or sensitive to expression of the 5 -phosphatase enzyme (n = 10 cells). Similar to the calmidazoliumprovoked Ca 2+ entry after run-down of SOCE ( Figure 5A ), AA evoked a substantial Ca 2+ entry after the decrease in SOCE (Figure 7C) , and this AA-induced Ca 2+ entry was completely inhibited by LOE-908 (30 µM; n = 35 cells). The AA-activated pathway was also permeable to Sr 2+ ( Figure 7D ) and not blocked by acute addition of 1 µM Gd 3+ (n = 120 cells). In all respects, the Ca 2+ influx pathway activated by AA resembled that observed with calmidazolium stimulation. Neither linolenic acid (n = 60 cells) nor linoleic acid (n = 32 cells) activated Ca 2+ influx. Although the experiments presented above indicate that AA production can stimulate the non-SOCE pathway, they do not implicate AA itself as the sole activator since it can be readily metabolized. We therefore examined the effect of inhibiting pathways responsible for AA metabolism. Lipoxygenase and cyclo-oxygenase enzymes convert AA into leukotrienes and prostaglandins, prostacyclins and thromboxanes respectively. Incubation of cells with the cyclo-oxygenase inhibitor indomethacin (10 µM; 25-90 min incubation in different experiments) did not alter basal Ca 2+ levels or prevent Ca 2+ signals evoked by calmidazolium (n = 45 cells). Similarly, the lipoxygenase inhibitor aspirin (100 µM; 30-90 min incubation in different experiments) had no effect (n = 30 cells). Finally, metabolism of AA via mono-oxygenases was prevented by using 100 µM metyrapone, which also did not alter Ca 2+ mobilization or Ca 2+ influx in response to calmidazolium (n = 20 cells). Calmidazolium belongs to a family of substituted imidazole compounds including econazole and miconazole. These compounds have a similar structure to calmidazolium, and may also affect CaM, although they are more commonly employed as inhibitors of cytochrome P450 mono-oxygenases. As with calmidazolium, 20 µM econazole and 20 µM miconazole evoked Ca 2+ mobilization and Ca 2+ entry. Coapplication of maximal concentrations (10 µM calmidazolium, 20 µM econazole and 20 µM miconazole) of these imidazole compounds indicated that their Ca 2+ responses were not additive (results not shown), suggesting that they activated the same Ca 2+ influx pathway. 
Mechanistic differences between SOCE-and calmidazolium-activated non-SOCE
To distinguish further between SOCE and the AA-activated Ca 2+ entry pathway in HeLa cells, we examined the effect of remodelling the cytoskeleton to produce a cortical actin deposition. This technique was used previously to inhibit SOCE activation [14, 15, 48] . Reorganization of the actin cytoskeleton was achieved by incubating HeLa cells with jasplakinolide (10 µM; 30 min preincubation), and monitored by confocal imaging of EGFPactin-transfected cells. In control cells, there was a largely homogeneous pool of fluorescence, reflecting monomeric proteins, but with fluorescent stress fibres also visible. After treatment with jasplakinolide, the EGFP-tagged actin redistributed to the subplasmalemmal region of cells ( Figure 8A ). This treatment abolished the entry of barium (Ba 2+ ), which was used as a slowly permeant surrogate for Ca 2+ through the SOCE pathway (Figure 8B) . However, it did not prevent Ba 2+ entry stimulated by calmidazolium ( Figure 8B ).
Similar to previous results [49] , we have observed that incubation of cells with ionomycin causes retraction of the ER (endoplasmic reticulum) from the plasma membrane and fragmentation into discrete vesicles [50] . In Ca 2+ -containing medium, such ionomycin-induced ER fragmentation and retraction occurs within approx. 5 min to 100 % of cells examined (n > 500 (Figure 1 ). The release of Ca 2+ from intracellular stores was blocked by U73122 and caffeine (Figure 2) , established antagonists of PLC-mediated Ins(1,4,5)P 3 production. Furthermore, calmidazolium released Ca 2+ from the same pool as histamine ( Figures 1D and 1E) , in an Ins(1,4,5)P 3 -dependent manner (Figure 2D) . Activation of PLC and production of Ins(1,4,5)P 3 In addition to stimulation of PLC, calmidazolium activated a non-SOCE pathway. This Ca 2+ entry mechanism was demonstrably different from SOCE based on its pharmacological profile (Figures 2A-2C , 3B and 4A-4D), ion selectivity ( Figure 4E ), lack of sensitivity to remodelling actin in a cortical ring ( Figure 8B ) or ionomycin-induced fragmentation and retraction of the ER ( Figure 8B ). The activation of non-SOCE by calmidazolium appeared to be due to stimulation of PLA 2 since inhibition of this enzyme completely prevented Ca 2+ influx in response to calmidazolium. Furthermore, the product of PLA 2 activation, AA, was capable of stimulating a non-SOCE pathway with exactly the same pharmacological profile (Figures 7A and 7B ) and ion selectivity ( Figure 7D ) as calmidazolium itself. Inhibition of lipoxygenase, cyclo-oxygenase and mono-oxygenase pathways did not alter the ability of calmidazolium to trigger Ca 2+ influx, suggesting that AA is the messenger responsible for the activation of non-SOCE.
Of all the metabolites demonstrated to activate non-SOCE, possibly the most commonly effective moiety is AA. This polyunsaturated fatty acid has been demonstrated to activate Ca 2+ influx in a variety of different cell types [7, [20] [21] [22] 51, 52] . In the present study, we observed that addition of AA to cells rapidly inhibited SOCE and switched the mode of Ca 2+ influx to LOE-908-sensitive non-SOCE ( Figure 7C ). Calmidazolium also switched the pathway of Ca 2+ influx from SOCE to LOE-908-sensitive non-SOCE ( Figure 3B ), although it caused a more rapid changeover when compared with AA. These results suggest that AA is a dominant Ca 2+ influx effector over the SOCE mechanism, and that the pathways do not function in an additive manner. We found that both calmidazolium and AA could activate Ca 2+ entry despite an ongoing SOCE response (e.g. Figures 3A and 7C) . Addition of either of the compounds at the peak or plateau phase of a thapsigargin response, triggered non-SOCE, suggesting that this mechanism is not particularly sensitive to ambient Ca 2+ levels. It therefore appears to us that the exclusivity of these Ca 2+ influx pathways reflects the dominance of AA, it shuts off SOCE and promotes non-SOCE.
Our results have some similarity to the recent study of Bolotina and co-workers [45] , who demonstrated that low concentrations of calmidazolium stimulated 2-APB-sensitive SOCE, whereas higher doses of calmidazolium invoked a 2-APB-insensitive Ca 2+ influx. Similar to the results of the present study, Bolotina and co-workers suggested that the key target of calmidazolium was PLA 2 . They focused on the effects of low calmidazolium concentrations and suggested that the lysophospholipids produced by PLA 2 caused SOCE activation. We have characterized the Ca 2+ entry generated by higher concentrations of calmidazolium and found that AA probably plays a significant role. Calmidazolium therefore appears to be capable of activating both SOCE and non-SOCE depending on its concentration. Both effects stem from the activation of PLA 2 , but may depend on the balance between lysophospholipids and AA.
Although they are widely used, cellular actions of CaM antagonists are not fully resolved. The consistent observation that they increase cytosolic Ca 2+ is problematic considering that they are generally used to antagonize downstream actions of Ca 2+ . Concentration-dependent Ca 2+ increases have been reported using various cell types in response to CaM antagonists including TFP, W-7, fendiline, chlorpromazine as well as calmidazolium. For most of these agents, the mechanism by which they cause Ca 2+ signals is not known. Calmidazolium is perhaps one of the best understood and is known to affect Ins(1,4,5)P 3 Rs [53] , SERCA1 Ca 2+ pumps [54] and L-type voltage-operated Ca 2+ channels [55] . Consistent with our observations, calmidazolium has been demonstrated to cause Ins(1,4,5)P 3 production through activation of PLC in several cell types (see e.g. [34, 56] ). Furthermore, calmidazolium activated Ca 2+ release and Ca 2+ entry in MadinDarby canine kidney cells, with the effects being abolished by the PLA 2 inhibitor aristolochic acid [34] .
Accumulating evidence suggests that CaM is a significant regulator of SOCE activity. CaM may prevent Ca 2+ entry by interfering with the physical coupling of Ins(1,4,5)P 3 Rs and SOCE channels. C-terminal portions of different TRPCs have been demonstrated to bind CaM or an N-terminal sequence of Ins(1,4,5)P 3 Rs in a mutually exclusive manner [27, 57, 58] . Displacement of CaM by short peptides corresponding to the competing region of Ins(1,4,5)P 3 Rs leads to activation of TRP channels [30] . CaM therefore appears to act as a barrier in the activation of Ca 2+ entry by occluding the site through which TRPs and Ins(1,4,5)P 3 Rs interact. Consistent with this notion, application of CaM antagonists (W-7 and TFP) significantly reduced the delay in development of SOCE after store depletion, whereas increasing CaM concentration caused the converse [28] . Furthermore, calmidazolium was capable of enhancing TRP activity by displacing CaM from the site where it prevented interaction with Ins(1,4,5)P 3 Rs [30, 57] . For Ins(1,4,5)P 3 Rs, CaM can bind to an N-terminal region and decrease the ability of Ins(1,4,5)P 3 to activate the channels [24, 59] . In addition, CaM may be responsible for the negative feedback effects of increased cytosolic Ca 2+ on Ins(1,4,5)P 3 R activation [23] . CaM therefore can provide both a tonic and a dynamic inhibitory influence on Ca 2+ release and entry in non-electrically excitable cells.
Although we suppose that the ability of calmidazolium to release Ca 2+ and activate non-SOCE was not due to CaM antagonism, we did observe an effect of calmidazolium on SOCE, which is consistent with the proposed inhibitory action of CaM. Activation of SOCE by thapsigargin allows the entry of Ca 2+ or Ba 2+ into HeLa cells. Ba 2+ is a useful surrogate, since it is poorly transported by cellular Ca 2+ pumps and therefore provides a unidirectional measure of cation entry. In the presence of ACA to prevent activation of non-SOCE, calmidazolium increased the rate of thapsigargin-stimulated Ba 2+ entry into cells by approx. 7-fold. In the absence of calmidazolium, the initial rate of Ba 2+ entry was 0.19 + − 0.04 ratio units/min (n = 5; measured using fura 2; see the Materials and methods section). In the presence of 10 µM calmidazolium, the rate of Ba 2+ entry was 1.26 + − 0.21 ratio units/min (n = 6). It therefore appears that calmidazolium does potentiate SOCE by working as a conventional CaM antagonist.
In summary, we have demonstrated that HeLa cells express two distinct Ca 2+ entry pathways, one regulated by store depletion and the other by AA. These pathways do not operate simultaneously due to the dominant effect of AA, which inhibits SOCE and promotes non-SOCE. The non-SOCE pathway can be directly activated by exogenous AA application, but in HeLa cells it is also robustly stimulated by calmidazolium. The effect of calmidazolium in promoting Ca 2+ release and non-SOCE is not due to CaM antagonism, but rather due to activation of PLC and PLA 2 . At present the function of the non-SOCE pathway in HeLa cells is not clear. Our attempts to find cellular agonists that couple with this pathway have so far proved negative. Histamine, ATP and serum all strongly activate Ca 2+ release in HeLa cells, which is followed by Ca 2+ entry. However, the Ca 2+ influx was sensitive to 1 µM Gd 3+ , which is indicative of SOCE. In addition, LOE-908 does not affect prolonged Ca 2+ oscillations activated by histamine (results not shown). Calmidazolium can stimulate Ca 2+ oscillations, but only in Ca 2+ -free medium when the non-SOCE pathway is not transporting Ca 2+ into the cells. Therefore, rather than supporting Ca 2+ oscillations, the non-SOCE channel appears to compromise the ability of HeLa cells to display repetitive Ca 
